Zomedica Q2 revenue up 43% to $6.0M; net loss flat at $5.3M; cash $142.4M

Zomedica Corp.

2023-Q2 EPS reported -$0.01 revenue$11,502,000

Revenue $6.0M vs $4.2M YoY (+43%); therapeutic segment $5.8M (+38%), diagnostic $0.2M (+100%).
Net loss $5.3M ($0.005/sh) unchanged YoY; adjusted non-GAAP EBITDA loss $3.1M.
Cash & equivalents $142.4M, down from $186.8M YoY; normalized operating burn ~$3M.
Gross margin 67%; adjusted >70% excluding one-time costs; consumable revenue $4.0M (+48% YoY).
Due diligence on potential SMP (VetGuardian) acquisition progressing; TRUVIEW digital microscopy launched late June.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Zomedica Corp. reported the quarter ended June 30, 2023 results: revenue $6.0 million.

Period: the quarter ended June 30, 2023
Revenue: $6.0 million
Result: reported results

Exact text from the filing

or incorporated by reference therein. --- EX-99.1 (EX-99.1) --- zom_ex991.htm EXHIBIT 99.1 Zomedica Announces Record Second Quarter 2023 Financial Results: Revenue up 43% to $6.0 Million; Strong 67% Gross Margin & $142.4 Million in Liquidity ANN ARBOR, MI / ACCESSWIRE / August 10, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a

View on SEC.gov

Browse all earnings releases →

Zomedica Corp. filing history →

Source: SEC EDGAR

accession 0001654954-23-010493

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.